Orientations
Change in vaccine vial monitor (VVM) assignment for GlaxoSmithKline Rotarix product
This information bulletin addresses the implications and required guidance associated with the upcoming scheduled shift in vaccine vial monitor (VVM) of the GlaxoSmithKline Biologicals SA (GSK) Rotavirus vaccine, Rotarix®, from VVM type 14 (VVM14) to VVM type 7 (VVM7). The information below is intended for WHO/UNICEF staff, as well as Expanded Program for Immunization (EPI) managers or other partner agencies which support immunization programmes.
Auteurs
Langues
- Anglais
Année de publication
2017
Éditeur
WHO
Type
Orientations
Catégories
- Gestion de programme
Maladies
- Rotavirus
Organisations
- Organisation Mondiale de la Santé (OMS)
Mots-clés
- Policy and legislation
Références sur le sujet
EPI-CORE-ROTA
| Titre | Auteur | Année | Type | Langue |
|---|---|---|---|---|
| Change in vaccine vial monitor (VVM) assignment for GlaxoSmithKline Rotarix product | World Health Organization (WHO) | 2017 | Guidance | Anglais |
| Generic protocol for monitoring impact of rotavirus vaccination on gastroenteritis disease burden and viral strains | World Health Organization (WHO) | 2009 | Guidance | Anglais |
| Manual of rotavirus detection and characterization methods | World Health Organization (WHO) | 2009 | Guidance | Anglais |
| Post-marketing surveillance of rotavirus vaccine safety | World Health Organization (WHO) | 2009 | Guidance | Anglais |
| Rotavirus vaccines: WHO position paper | World Health Organization (WHO) | Guidance | Arabe, Chinois, Anglais, Français, Russe, Espagnol |
